The global AI-based clinical trials solution providers market is anticipated to grow by a CAGR of ~22% over the forecast period, i.e., 2022 – 2031. The market is segmented by application into oncology, cardiovascular diseases, metabolic diseases, neurological diseases and others. Out of these, the oncology segment is anticipated to garner the largest revenue and further grow significantly in the coming years. Factors such as the increasing prevalence of cancer and the rising number of drug trials support the growth of the segment market.